// App-Quantinova.ai

3471 : Treatment of Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Using Tyrosine Kinase Inhibitors in Combination with Chemotherapy: A Patient-Centered Benefit-Risk Assessment

Researchers

Presenter

  • Ajibade O Ashaye

Principal Investigators

  • Caitlin Thomas

  • Mehul Dalal

  • Vamsi Kota

  • Nicolas Krucien

  • Maria Sae-Hau

  • Meredith Barnhart

  • Elisa S. Weiss

  • Scott Campbell

  • Kevin Marsh

Medical Centers

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Evidera, Inc., London, United Kingdom

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • The Leukemia & Lymphoma Society, Rye Brook, NY

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • 3β-hydroxysterol Δ24-reductase

  • Breakpoint Cluster Region

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved